TREM2-SYK microglial activation as a stage-specific Alzheimer's disease modifier
🧪 Overview
TREM2-SYK signaling controls microglial survival, plaque association, phagocytosis, and disease-associated microglial state transitions. The biology remains strong, but standalone TREM2 agonism in broad early Alzheimer's disease is weakened by recent clinical failure; future use should be stage-specific, biomarker-enriched, or combined with amyloid or tau-directed therapy.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2;
No curated PDB or AlphaFold mapping for TREM2; yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2; SYK.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |